The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Abstract
Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.Methods In EMPOWER-Lung 1, a multicentre, open-label, global, phase 3 study, eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0-1; never-smokers were ineligible) were randomly assigned (1:1) to cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. Crossover from chemotherapy to cemiplimab was allowed following disease progression. Primary endpoints were overall survival and progression-free survival per masked independent review committee. Primary endpoints were assessed in the intention-to-treat population and in a prespecified PD-L1 of at least 50% population (per US Food and Drug Administration request to the sponsor), which consisted of patients with PD-L1 of at least 50% per 22C3 assay done according to instructions for use. Adverse events were assessed in all patients who received at least one dose of the assigned treatment. This study is registered with ClinicalTrials.gov, NCT03088540 and is ongoing.Findings Between June 27, 2017 and Feb 27, 2020, 710 patients were randomly assigned (intention-to-treat population). In the PD-L1 of at least 50% population, which consisted of 563 patients, median overall survival was not reached (95% CI 17·9-not evaluable) with cemiplimab (n=283) versus 14·2 months (11·2-17·5) with chemotherapy (n=280; hazard ratio [HR] 0·57 [0·42-0·77]; p=0·0002). Median progression-free survival was 8·2 months (6·1-8·8) with cemiplimab versus 5·7 months (4·5-6·2) with chemotherapy (HR 0·54 [0·43-0·68]; p<0·0001). Significant improvements in overall survival and progression-free survival were also observed with cemiplimab in the intention-to-treat population despite a high crossover rate (74%). Grade 3-4 treatment-emergent adverse events occurred in 98 (28%) of 355 patients treated with cemiplimab and 135 (39%) of 342 patients treated with chemotherapy.Interpretation Cemiplimab monotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%, providing a potential new treatment option for this patient population.Funding Regeneron Pharmaceuticals and Sanofi.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It may result in better OS and PFS compared to platinum-based chemotherapy in patients with advanced NSCLC, indicating a possible new treatment option for these patients [51].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [51]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Self-citationInterpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Cited by
Sorted by citations
Items 401–500 of 795
Pettinella, F., Lattanzi, C., Donini, M., Caveggion, E., Marini, O., Iannoto, G., Costa, S. E., Zenaro, E., Fortunato, T. M., Gasperini, S., et al. (2023) · Cancers · doi:10.3390/cancers15215285 · Cited by 7
PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain
de Gordoa, K. S., López, I. A., Marginet, M., Coloma, B., Frigola, G., Vega, N., Martı́nez, D., & Teixidó, C. (2021) · Diagnostics · doi:10.3390/diagnostics11081452 · Cited by 8
Campelo, M. R. G., Arriola, E., Campos, B., López-Brea, M., Pradera, J. F., de Castro, J., Aguado, C., Parente, D. P., de Oro-Pulido, F., Gracia, P. R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194583 · Cited by 7
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7
Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
Rosell, R., & González‐Cao, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00196-3 · Cited by 7
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
Grecea, M., Şoriţău, O., Dulf, D. V., Ciuleanu, T., & Zdrenghea, M. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s283892 · Cited by 7
Yang, R., Gu, C., Xie, F., Hong, S., Herth, F. J. F., & Sun, J. (2024) · Respiration · doi:10.1159/000538383 · Cited by 6
Wu, J., Wang, H., Yang, R., Liu, D., & Li, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1449853 · Cited by 6
Liu, L., Yan, Y., Wang, Y., Li, Z., Yang, L., Yu, K., & Zhao, Z. (2025) · Oncology Letters · doi:10.3892/ol.2025.14903 · Cited by 7
Peters, S., Regan, M. M., Paz-Ares, L. G., Reck, M., Borghaei, H., O'Byrne, K. J., Brahmer, J. R., Penrod, J. R., Li, J., Tracy, L. A., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.019 · Cited by 6
Young lung cancer: from diagnosis to survivorship
Florez, N., Kiel, L., Kaufman, R. A., LoPiccolo, J., Ricciuti, B., Morabito, A. S., Fakorede, O., Mantz, C., Olazagasti, C., Swami, N. S., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570143 · Cited by 6
Inno, A., Veccia, A., D’Argento, E., Morgillo, F., Pizzutilo, E. G., Vitiello, F., Pavan, A., Lombardo, F., Russano, M., Sforza, V., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04125-w · Cited by 6
Feng, M., Niu, Y., Liu, J., & Liu, G. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01690-2 · Cited by 6
Bharadwaj, S., Mierzwicka, J. M., Vaňková, L., & Malý, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02410-w · Cited by 7
Li, S., Zhang, H., Liu, T., Chen, J., & Dang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702924 · Cited by 6
Self-citationLack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?
Wu, Q., Luo, S., & Xie, X. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000426 · Cited by 6
Zhao, Y., Chen, X., Yao, J., Long, J., Mao, Y., Wu, D., Zang, A., Zhao, J., Liu, Z., Meng, R., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.6855 · Cited by 6
Zhong, X., Sun, J., Zeng, N., Xiong, Y., An, Y., Wang, S., & Xia, Q. (2024) · Cancers · doi:10.3390/cancers16020382 · Cited by 6
Hui, W., Li, W., Song, R., Xin, Y., Wu, C., Gao, Z., Zhang, M., Wu, H., Zhu, M., & Cai, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12439-8 · Cited by 6
Xu, H., Fu, X., Wang, S., Ge, Y., Zhang, L., Li, J., Zhang, F., Yang, Y., He, Y., Sun, Y., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35360 · Cited by 6
Girard, N., Han, J., Soo, R. A., Wang, K., Tang, W., Nikolaidis, G. F., Tasoulas, A., Barouma, I., Castro, J. C., Yang, Z., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108450 · Cited by 6
Wang, M., Yang, J., Wang, S., Gill, H., & Cheng, H. (2025) · Current Oncology · doi:10.3390/curroncol32030171 · Cited by 7
Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Swanson, L. A., Kassab, I. A., Tsung, I., Worden, F. P., & Fontana, R. J. (2022) · Immunotherapy · doi:10.2217/imt-2021-0191 · Cited by 6
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management
Safa, H., Rous, F. A., Belani, N., Borghaei, H., Gadgeel, S. M., & Halmos, B. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00937-3 · Cited by 6
Current immune therapeutic strategies in advanced or metastatic non-small cell lung cancer
Xu, J., Liu, C., Wu, X., & Ma, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002536 · Cited by 6
Cho, B. C., Penkov, K., Bondarenko, I., Kurochkin, A., Pikiel, J., Ahn, H. K., Korozan, M., Osipov, M., Odintsova, S., Braiteh, F., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101589 · Cited by 6
Self-citationSwart, E. M., Noordhof, A. L., Damhuis, R. A. M., Kunst, P. W. A., Ruysscher, D. D., Hendriks, L. E. L., van Geffen, W. H., & Aarts, M. J. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107290 · Cited by 6
Roussos, P., & Migkou, M. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.09.004 · Cited by 6
Sala, I., Pagan, E., Pala, L., Oriecuia, C., Musca, M., Specchia, C., Pas, T. M. D., Cortés, J., Giaccone, G., Postow, M. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340979 · Cited by 7
Yuan, Q., Xu, C., Wang, W., & Zhang, Q. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241246651 · Cited by 6
Rossi, S., Masini, S., Finocchiaro, G., Lorenzi, E., Toschi, L., & Santoro, A. (2024) · Cancers · doi:10.3390/cancers16091683 · Cited by 6
Ferrari, V., & Hélissey, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092715 · Cited by 6
Xiong, L., Cai, Y., Zhou, X., Dai, P., Wei, Y., Zhao, J., & Tang, H. (2021) · Future Oncology · doi:10.2217/fon-2021-1217 · Cited by 6
Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?
Kaen, D. L., Minatta, N., Russo, A., Malapelle, U., de Miguel‐Pérez, D., & Rolfo, C. D. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_4 · Cited by 6
Kim, J. H., Jeong, S. Y., Lee, J., Park, S. T., & Kim, H. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061492 · Cited by 7
PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer
Guo, L., Liang, J., Dai, W., Li, J., Si, Y.-X., Ren, W., Lu, Y., & Chen, D. (2022) · Cancer Control · doi:10.1177/10732748221107590 · Cited by 6
Vaes, R. D. W., Cortiula, F., Lyu, S., Hiltermann, T. J. N., Houben, R. M. A., Degens, J. H. R. J., Hendriks, L. E. L., & Ruysscher, D. D. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108541 · Cited by 5
Giglio, A. D., Zullo, L., Federico, A. D., Cani, M., Aldea, M. D., Soldato, D., Dall’Olio, F. G., Mantuano, F., Sperandi, F., Favorito, V., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105897 · Cited by 5
Frost, N., Joosten, M., Franzen, J., Wiesweg, M., Rasokat, A., Kulhavy, J., Kollmeier, J., Reinmuth, N., Grohé, C., Roeper, J., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.12.011 · Cited by 5
Xiao, Z., Sun, L., Zheng, Y., Chen, H., Zheng, X., Luo, J., Gu, C., Lin, R., Huang, M., Bai, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-746 · Cited by 5
Nguyen, T.-A., Le, M., Nguyen, P.-T., Tran, N. Q. V., Kondo, T., & Nakao, A. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-334 · Cited by 5
Melosky, B. L., Vincent, M. D., McGuire, A., Brade, A. M., Chu, Q. S.-C., Cheema, P. K., Martins, I., Spicer, J. D., Snow, S. L., & Juergens, R. A. (2024) · International Journal of Cancer · doi:10.1002/ijc.35031 · Cited by 5
Gandara, D. R., Subramanian, J., Santos, E. S., Brody, Y., Sela, I., Elon, Y., Harel, M., Benaim, A. R., Lahav, C., & McGregor, K. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.06.011 · Cited by 5
Kalkan, Z., Ebinç, S., Arcagök, M., Bilici, A. E., Yıldız, Ö., Kılıçkap, S., Güven, D. C., Tatlı, A. M., Sümbül, A. T., Mandel, N. M., et al. (2025) · Medicina · doi:10.3390/medicina61040638 · Cited by 5
Dou, Z., Wang, L., Rui, M., Yang, Y., Zhou, Y., Zhang, J., Zhao, Q., Wang, M., Wang, H., Zhang, X., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70101 · Cited by 5
del Corral-Morales, J., Miguel, C. A.-D., Cortés, L. Q., Sanchez-Vegas, A., Aranda-Bellido, F., González-Santiago, S., Fuentes, J., & Miguel, P. A.-D. (2025) · Cancers · doi:10.3390/cancers17132194 · Cited by 5
Tumor-infiltrating lymphocytes in NSCLC: from immune surveillance to immunotherapy
Xue, H., Fan, Y., Li, Y., Zhao, Q., Zhang, X., Zhao, P., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610998 · Cited by 7
Zhang, M., Liu, X., Wen, F., Wu, Q., Zhou, K., Bai, L., & Li, Q. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.10.008 · Cited by 5
Freemantle, N., Xu, Y., Wilson, F. R., Guyot, P., Chen, C.-I., Keeping, S., Konidaris, G., Chan, K., Kuznik, A., Atsou, K., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221105024 · Cited by 5
Self-citationNew Implications of Patients’ Sex in Today’s Lung Cancer Management
Raskin, J., Snoeckx, A., Janssens, A., Bondt, C. D., Wener, R. R. L., van de Wiel, M., van Meerbeeck, J. P., & Smits, E. (2022) · Cancers · doi:10.3390/cancers14143399 · Cited by 5
Ge, W., Wu, N., Quek, R. G. W., Liu, J., Pouliot, J., Dietz, H., Jalbert, J. J., Harnett, J., & Antonia, S. J. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02260-9 · Cited by 5
Garon, E. B., Spira, A. I., Goldberg, S. B., Chaft, J. E., Papadimitrakopoulou, V. A., Cascone, T., Antonia, S. J., Brahmer, J. R., Camidge, D. R., Powderly, J. D., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.04.020 · Cited by 5
Checkpoint inhibitors in older patients with advanced non-small cell lung cancer
Reale, M. L., Romano, G. D., Paolelli, L., & Leo, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104056 · Cited by 5
Brazel, D., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s413611 · Cited by 5
Liu, W., Huo, G., & Chen, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1163381 · Cited by 5
Sawa, K., Ihara, Y., Imai, T., Sugimoto, A., Nagamine, H., Ogawa, K., Nakahama, K., Matsumoto, Y., Tani, Y., Kaneda, H., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.11.003 · Cited by 5
Phillips, W., Thornton, Z. A., Andrews, L., Daly, R. G., Higgins, J. P. T., Davies, P. A., & Kurian, K. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104288 · Cited by 5
Yamani, N., Ahmed, A. B., Ruiz, G. S., Zubair, A., Arif, F., & Mookadam, F. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00229-x · Cited by 6
A narrative review on perioperative systemic therapy in non-small cell lung cancer
Hsu, R. C., Arter, Z., Poei, D., & Benjamin, D. J. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00256 · Cited by 5
Barrichello, A. P. D. C., Elkrief, A., Ricciuti, B., Ganta, T., Marron, T. U., Wang, X., Lotter, W. E., Lindsay, J. R., Santo, V., Cortellini, A., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.01.014 · Cited by 5
Nicolini, A., Ferrari, P., Silvestri, R., & Bini, D. A. (2025) · MedComm · doi:10.1002/mco2.70373 · Cited by 5
Varlotto, J. M., Sun, Z., Ky, B., Upshaw, J. N., FitzGerald, T. J., Diehn, M., Lovly, C. M., Belani, C. P., Oettel, K. R., Masters, G. A., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.005 · Cited by 6
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity
Fahey, C. C., Gracie, T. J., & Johnson, D. B. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2215435 · Cited by 5
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
Mogavero, A., Cantale, O., Mollica, V., Anpalakhan, S., Addeo, A., Mountzios, G., Friedlaender, A., Kanesvaran, R., Novello, S., & Banna, G. L. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2302356 · Cited by 5
Non-small cell lung cancer in the era of immunotherapy
Huang, Q., Kemnade, J. O., Cornwell, L., Kheradmand, F., Sabichi, A. L., & Das, D. G. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.009 · Cited by 6
Mechanism of Action and Pharmacologic Features of Drugs Targeting PD ‐1/ PDL ‐1 and CTLA ‐4
Rodriguez, M., Bucktrout, R., Orlando, A., Serganova, I. S., & Zappasodi, R. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch11 · Cited by 5
Resuli, B., Kauffmann-Guerrero, D. E., Lasso, M. N. A., Behr, J., & Tufman, A. (2025) · Diagnostics · doi:10.3390/diagnostics15151937 · Cited by 4
Lima, I. G., da Silva, I. B. U. C., Pípolo, V. C., Delfino, V. D. A., & Bignardi, P. R. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2360071 · Cited by 4
Colonese, F., Bulotta, A., Genova, C., Signorelli, D., Bonanno, L., Proto, C., Panel, I. I. N. D., & Cortinovis, D. L. (2024) · Biomedicines · doi:10.3390/biomedicines12122742 · Cited by 4
Coniac, S., Costache-Outas, M. C., Antone-Iordache, I.-L., Barbu, A.-M., Bardan, V. T., Zamfir, A., Ionescu, A.-I., & Badiu, C. (2025) · Cancers · doi:10.3390/cancers17071198 · Cited by 4
Immune-checkpoint inhibitor resistance in patients with cancer
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003196 · Cited by 4
Zhou, L., Uemura, T., Abbar, B., & Deng, S. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-754 · Cited by 6
Oresti, S., Salomone, F., Nuccio, A., Ogliari, F. R., Riva, S. T., Mollica, L., Bulotta, A., Viganò, M. G., Venanzi, F. M., Passaretti, F., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103482 · Cited by 4
Liu, N., Zhang, B., He, J., & Su, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635757 · Cited by 4
Leone, G. M., Scuderi, G., Fagone, P., & Mangano, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211055 · Cited by 4
Puglisi, M. M., May, L., Gardiyehewa, T., & Landry, J. W. (2025) · Cancers · doi:10.3390/cancers17243953 · Cited by 4
Peng, L., Stebbing, J., Liang, F., & Xia, Y. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-650 · Cited by 4
Bertin, L., Canellas, A., Abbar, B., Veyri, M., Spano, J., Cadranel, J. L., & Lavolé, A. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100247 · Cited by 4
Medusa, P. M., Gilli, M., Notizia, L., Pagliaro, R., Carro, N., Moriello, A., D’Agnano, V., Bianco, A., Perrotta, F., & Vitiello, F. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2440 · Cited by 4
Barbosa, E. C., Bucar, E. E. C., JUBÉ, G. R., SILVEIRA, L. B., SILVA, N. C. D., FARIA, P. C. C., Ramos, P., Moraes, V. R. Y., & BARROS, J. O. B. (2023) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20233490-en · Cited by 5
Sun, H., Bu, F., Li, L., Zhang, X., Xin, X. L., Yan, J., & Huang, T. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231188171 · Cited by 4
Min, Y., Zhu, Y., Ye, M., Zhu, Q., Xu, Y., & Li, X. (2023) · Medicine · doi:10.1097/md.0000000000035678 · Cited by 4
Recent death early warning value of ECG changes in patients with NSCLC
Liu, Q., Cai, W., Wang, X., Hu, H., Sun, X., Pan, X., & Wang, A. (2023) · Medicine · doi:10.1097/md.0000000000035698 · Cited by 4
Brown, L. J., Ahn, J. J., Gao, B., Gee, H. E., Nagrial, A. M., Hau, E. K. C., & da Silva, I. P. (2024) · Cancers · doi:10.3390/cancers16112136 · Cited by 4
Self-citationLi, H., Liu, J., Zhang, L., Xu, Y., Wang, X., Lan, S., Cui, P. L., Wang, G., Cai, S., & Cheng, Y. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009693 · Cited by 4
Gemelli, M. T., Bidoli, P., Colonese, F., Canova, S., & Cortinovis, D. L. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s562 · Cited by 4
Kandemir, E. A. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221112015 · Cited by 5
Pîrlog, C.-F., Costache, R. S., Paroșanu, A. I., Slavu, C. O., Olaru, M., Popa, A. M., Iaciu, C. I., Niță, I., Motatu, P., Cotan, H. T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13111892 · Cited by 4
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
Reyes, A., Pharaon, R. R., Mohanty, A. R., & Massarelli, E. (2023) · Cancers · doi:10.3390/cancers15123162 · Cited by 4
Wei, J., Yuile, A., Itchins, M., Kong, B. Y., Li, B. T., Pavlakis, N., Chan, D. L. H., & Clarke, S. J. (2023) · Biomedicines · doi:10.3390/biomedicines11071827 · Cited by 4
Jackson, A. J., Chang, N., Akurang, D., Wheatley‐Price, P., & Moore, S. M. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100601 · Cited by 5
Ferreira, M., Sécher, T., Heuzé‐Vourc'h, N., & Reckamp, K. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060912 · Cited by 4
Cemiplimab: a New Option for the Treatment of Non-Small-Cell Lung Cancer
Khalife, N., Kordahi, M., Felefly, T., & Saleh, K. (2021) · Future Oncology · doi:10.2217/fon-2021-0343 · Cited by 4
Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine
Kuronishi, M., Ozawa, Y., Kimura, T., Li, S. D., & Kato, Y. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0403 · Cited by 3
Self-citationCarbone, M., Amos, C. I., Attanoos, R. L., Boeri, M., Bueno, R., Bunn, P. A., Chirieac, L. R., Cooper, B. T., Fennell, D. A., Galateau-Sallé, F., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.002 · Cited by 4
Newsom-Davis, T. E., Melosky, B. L., Heist, R. S., Lu, S., Pasello, G., Chen, X., Stachowiak, M., Lyfar, P., Forcina, A., & Ramalingam, S. S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1721624 · Cited by 4
Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients
Tao, D., Lei, H., Sun, L., Wang, L., Zhou, W., Wang, Y., & Wu, Y. (2026) · BMC Cancer · doi:10.1186/s12885-026-15729-5 · Cited by 3
Abnormally High Expression of DNAJB6 Accelerates Malignant Progression of Lung Adenocarcinoma
Wang, D., Xiao, J., Du, Y., Zhang, L., & Qin, X. (2024) · Biomedicines · doi:10.3390/biomedicines12091981 · Cited by 3
Tsuruda, K. M., Hektoen, H. H., Aamelfot, C., & Kulle, B. (2025) · International Journal of Cancer · doi:10.1002/ijc.35445 · Cited by 3
Metadata
- Authors
- Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Gao, B., Li, S., Lee, S., McGuire, K., Chen, C.-I., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D. M., Yancopoulos, G. D., Gullo, G., Lowy, I., & Rietschel, P.
- Affiliations
- Başkent University (TR)
- Istanbul Medeniyet University (TR)
- Dnipro State Medical University (UA)
- Istanbul University-Cerrahpaşa (TR)
- University of Wollongong (AU)
- Chulalongkorn University (TH)
- Columbia University Irving Medical Center (US)
- Regeneron (United States) (US)
- Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser (RU)
- Corresponding author
- Sezer, Ahmet
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 397
- Issue
- 10274
- Pages
- 592-604
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3129022890
- Cited by
- 789
- References
- 31
- Citations by year
- 2026: 52 · 2025: 133 · 2024: 164 · 2023: 197 · 2022: 167 · 2021: 74
- FWCI
- 54.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- cemiplimab, non-small cell lung cancer, PD-L1 expression, PD-1 inhibitors, first-line therapy, platinum-based chemotherapy, overall survival, progression-free survival, immune checkpoint inhibitors, treatment crossover, adverse events, immune-related adverse events, immunotherapy versus chemotherapy, never smokers
- MeSH terms
- Pemetrexed, Antineoplastic Agents, Immunological, Progression-Free Survival, Immune Checkpoint Inhibitors, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Rate, Carboplatin, Paclitaxel, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
